---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-045997"
form_type: "8-K"
ticker: "VCEL"
cik: "0000887359"
company_name: "Vericel Corp"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T04:11:01.809735+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vericel Q3 revenue up 27% to $57.9M; raises full-year margin guidance

## Summary
- Total net revenue $57.9M (+27% YoY); MACI $44.7M (+19%), Burn Care $13.2M (+66%).
- Gross margin 72% (+480bps YoY); net loss narrowed to $0.9M ($0.02/share) from $3.7M.
- Adjusted EBITDA $10.0M (+84%, margin 17%); raised FY24 guidance: gross margin 72%, adj. EBITDA margin 22%.
- FDA approved MACI Arthro for knee cartilage repair; NexoBrid pediatric indication also approved.
- Cash $151M, no debt; operating cash flow $10.2M in Q3.

## SEC filing metadata
- accession: 0001628280-24-045997
- form_type: 8-K
- ticker: VCEL
- cik: 0000887359
- company_name: Vericel Corp
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/887359/000162828024045997/0001628280-24-045997-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/887359/000162828024045997/vcel-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-045997
- JSON: https://secwatch.observer/filing/0001628280-24-045997.json
- Plain text: https://secwatch.observer/filing/0001628280-24-045997.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.